Multicenter trial of naloxone in Alzheimer's disease.

Abstract

In a double-blind, placebo-controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1-mg or 10-mg doses; 15 patients at 1 center were similarly unimproved after… (More)

Topics

  • Presentations referencing similar topics